These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 31903795)

  • 1. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-agnostic biomarker-guided oncology drug development.
    Jørgensen JT
    Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An appraisal of drug development timelines in the Era of precision oncology.
    Jardim DL; Schwaederle M; Hong DS; Kurzrock R
    Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
    Adashek JJ; Subbiah V; Kurzrock R
    Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations.
    Babiker HM; Davis L; Larson K; Placencia C; Swensen C; Tenneti P; Lim M; Cañamar R; Curtis J; Castillo E; Mancuso J; Rensvold D; Martinez S; Macias L; Recio-Boiles A; Chandana SR; Mahadevan D
    Expert Opin Investig Drugs; 2019 Aug; 28(8):675-686. PubMed ID: 31327293
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
    Shimazawa R; Ikeda M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ushering in the next generation of precision trials for pediatric cancer.
    DuBois SG; Corson LB; Stegmaier K; Janeway KA
    Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of precision oncology trials: challenges and opportunities.
    Fountzilas E; Tsimberidou AM
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):797-804. PubMed ID: 30044653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
    Jardim DL; Schwaederle M; Wei C; Lee JJ; Hong DS; Eggermont AM; Schilsky RL; Mendelsohn J; Lazar V; Kurzrock R
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26378224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
    Marquart J; Chen EY; Prasad V
    JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward a More Precise Future for Oncology.
    Murciano-Goroff YR; Taylor BS; Hyman DM; Schram AM
    Cancer Cell; 2020 Apr; 37(4):431-442. PubMed ID: 32289268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.